SBRT Versus Surgical Resection for Small HCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related incidence and mortality in China and represents a major public health challenge. Surgical resection is the most commonly used curative treatment for HCC and can provide favorable long-term outcomes. However, resection is associated with substantial perioperative morbidity, and its applicability is limited in certain patient populations, including those with recurrent disease, those who have undergone conversion therapy, and those with significant coexisting medical conditions. Advances in radiotherapy technology and the development of highly precise delivery techniques have led to the increasing use of stereotactic body radiotherapy (SBRT) in the management of HCC, particularly in patients with small tumors. Randomized controlled trials conducted by our group have shown that, in patients with recurrent small HCC, SBRT provides superior local tumor control compared with radiofrequency ablation. These findings suggest that SBRT may represent a potentially curative treatment option for selected patients with small HCC. On the basis of this evidence, the present study is designed to compare the efficacy and safety of surgical resection and SBRT in patients with small HCC. Patients with a solitary tumor measuring 5 cm or less in maximum diameter will be randomly assigned to undergo either surgical resection or SBRT. The primary end point of the study is overall survival. This trial aims to define the relative benefits and risks of these two treatment strategies and to provide high-quality evidence to inform clinical decision making and future guideline recommendations.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony rak wątroby (rak pierwotny)
- •Jeden guz nie większy niż 5 cm
- •Brak przerzutów do innych organów i węzłów chłonnych
- •Lekarz stwierdza, że pacjent nadaje się do obu sposobów leczenia
- •Sprawna wątroba (klasa Child-Pugh A)
- •Ogólny stan zdrowia pozwalający na leczenie (wynik Karnofsky'ego ≥90)
- •Spodziewana długość życia co najmniej 6 miesięcy
✗ Disqualifies
- •Poważne problemy z pracą głównych narządów
- •Pacjent nie potrafi lub nie chce dać pisemnej zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Sun Yat-sen University Cancer Center
Guangzhou, China
Trial contact
Minshan Chen, PhD, MD
Yaojun Zhang, PhD, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.